CN103596935A - Cxcr4拮抗剂的用途 - Google Patents

Cxcr4拮抗剂的用途 Download PDF

Info

Publication number
CN103596935A
CN103596935A CN201280024014.6A CN201280024014A CN103596935A CN 103596935 A CN103596935 A CN 103596935A CN 201280024014 A CN201280024014 A CN 201280024014A CN 103596935 A CN103596935 A CN 103596935A
Authority
CN
China
Prior art keywords
methylene
bis
phenylenebis
tetraazacyclotetradecane
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280024014.6A
Other languages
English (en)
Chinese (zh)
Inventor
D.C.戴尔
G.J.布里杰
F.J.许
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Genzyme Corp
Original Assignee
University of Washington
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Genzyme Corp filed Critical University of Washington
Publication of CN103596935A publication Critical patent/CN103596935A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201280024014.6A 2011-05-16 2012-05-15 Cxcr4拮抗剂的用途 Pending CN103596935A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486632P 2011-05-16 2011-05-16
US61/486,632 2011-05-16
PCT/US2012/037970 WO2012158707A1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists

Publications (1)

Publication Number Publication Date
CN103596935A true CN103596935A (zh) 2014-02-19

Family

ID=81755014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280024014.6A Pending CN103596935A (zh) 2011-05-16 2012-05-15 Cxcr4拮抗剂的用途

Country Status (11)

Country Link
US (2) US20150030561A1 (enExample)
EP (1) EP2709991B1 (enExample)
JP (1) JP2014513727A (enExample)
KR (3) KR20200016407A (enExample)
CN (1) CN103596935A (enExample)
BR (1) BR112013029482A2 (enExample)
ES (1) ES2831049T3 (enExample)
MX (1) MX365242B (enExample)
PL (1) PL2709991T3 (enExample)
RU (1) RU2638802C2 (enExample)
WO (1) WO2012158707A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427513A (zh) * 2014-09-30 2017-12-01 太景生物科技股份有限公司 治疗癌症及心肌梗塞的方法
CN108883091A (zh) * 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
CN109563152A (zh) * 2016-03-11 2019-04-02 普罗克斯马根有限责任公司 Cxcr4拮抗剂和免疫检查点抑制剂的组合
CN109641838A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109988153A (zh) * 2017-12-29 2019-07-09 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
CN113662937A (zh) * 2021-10-09 2021-11-19 江苏省人民医院（南京医科大学第一附属医院） Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途
CN116675708A (zh) * 2023-04-23 2023-09-01 华南师范大学 一类氧化响应的大环化合物、大环配合物及其应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212988A (zh) 2005-05-02 2008-07-02 建新公司 神经代谢疾病的基因治疗
US9788466B2 (en) 2013-04-16 2017-10-10 Skyworks Solutions, Inc. Apparatus and methods related to ground paths implemented with surface mount devices
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
AU2017322511B2 (en) * 2016-09-08 2021-08-26 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Gene therapy for patients with Fanconi anemia
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
EP4232058A1 (en) * 2020-10-20 2023-08-30 Eom Pharmaceuticals Inc. Eom613 for treatment of covid-19
WO2025122961A1 (en) * 2023-12-08 2025-06-12 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1338933A (zh) * 1999-02-02 2002-03-06 阿诺医药公司 升高白血细胞数量的方法和组合物
US20080234294A1 (en) * 2005-08-18 2008-09-25 Novartis Ag Cxcr4 Binding Molecules
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics, Inc. Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
HK1046409A1 (zh) 1999-12-17 2003-01-10 Anormed Inc. 结合趋化因子受体的杂环化合物
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20070160574A1 (en) 2000-04-12 2007-07-12 Ahmed Merzouk Design of CXC chemokine analogs for the treatment of human diseases
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
EP2022787B1 (en) 2000-09-29 2012-11-28 Genzyme Corporation Process for the preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
US6987102B2 (en) 2001-07-31 2006-01-17 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
CA2521416A1 (en) 2003-04-02 2004-10-21 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
CA2577046A1 (en) 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006095542A1 (ja) 2005-03-04 2006-09-14 Kureha Corporation アミン系化合物を含む医薬組成物
CN101365336B (zh) 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
BRPI0621369A2 (pt) 2006-02-24 2011-12-06 Genzyme Corp uso de compostos que ligam-se ao receptor quimiocina cxcr4 e métodos para aumentar o fluxo de sangue e promover a regeneração do tecido
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
AR063470A1 (es) 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
US20100178271A1 (en) 2006-08-07 2010-07-15 Genzyme Corporation Combination Therapy
BRPI0721259C1 (pt) 2007-02-28 2021-05-25 Polyphor Ltd composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
EP2291963B1 (en) 2008-06-23 2016-04-27 BlackBerry Limited Method for delivering device and server capabilities
US20110245265A1 (en) 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
EP2384115A4 (en) * 2009-01-30 2012-11-07 Genzyme Corp METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANT TUMORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1338933A (zh) * 1999-02-02 2002-03-06 阿诺医药公司 升高白血细胞数量的方法和组合物
US20080234294A1 (en) * 2005-08-18 2008-09-25 Novartis Ag Cxcr4 Binding Molecules
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BE´ATRICE LABROSSE等: "Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100", 《JOURNAL OF VIROLOGY》 *
MARCO A. C. NEVES等: "Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach", 《J COMPUT. AIDED MOL DES》 *
MARCO A. C. NEVES等: "Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach", 《J COMPUT. AIDED MOL DES》, vol. 24, no. 12, 31 December 2010 (2010-12-31), XP019863448, DOI: doi:10.1007/s10822-010-9393-x *
NATHALIE SIGNORET等: "Differential regulation of CXCR4 and CCR5 endocytosis", 《JOURNAL OF CELL SCIENCE》 *
RAFFAELE BADOLATO等: "Mechanisms of WHIM syndrome", 《DRUG DISCOVERY TODAY: DISEASE MECHANISMS》 *
RAFFAELE BADOLATO等: "Mechanisms of WHIM syndrome", 《DRUG DISCOVERY TODAY: DISEASE MECHANISMS》, vol. 2, no. 4, 31 December 2005 (2005-12-31), XP005213116, DOI: doi:10.1016/j.ddmec.2005.11.010 *
SETH A. FAITH等: "Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation", 《VIROLOGY》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427513A (zh) * 2014-09-30 2017-12-01 太景生物科技股份有限公司 治疗癌症及心肌梗塞的方法
CN108883091A (zh) * 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
CN109563152A (zh) * 2016-03-11 2019-04-02 普罗克斯马根有限责任公司 Cxcr4拮抗剂和免疫检查点抑制剂的组合
CN109641838A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109988153A (zh) * 2017-12-29 2019-07-09 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
CN113662937A (zh) * 2021-10-09 2021-11-19 江苏省人民医院（南京医科大学第一附属医院） Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途
CN116675708A (zh) * 2023-04-23 2023-09-01 华南师范大学 一类氧化响应的大环化合物、大环配合物及其应用

Also Published As

Publication number Publication date
KR20140045411A (ko) 2014-04-16
MX365242B (es) 2019-05-28
EP2709991A4 (en) 2014-10-01
MX2013013308A (es) 2014-02-27
KR20210094672A (ko) 2021-07-29
US20150030561A1 (en) 2015-01-29
ES2831049T3 (es) 2021-06-07
RU2013155601A (ru) 2015-06-27
JP2014513727A (ja) 2014-06-05
KR20200016407A (ko) 2020-02-14
EP2709991A1 (en) 2014-03-26
EP2709991B1 (en) 2020-09-02
BR112013029482A2 (pt) 2016-08-09
US20210161859A1 (en) 2021-06-03
PL2709991T3 (pl) 2021-04-06
WO2012158707A1 (en) 2012-11-22
RU2638802C2 (ru) 2017-12-15

Similar Documents

Publication Publication Date Title
US20210161859A1 (en) Use of cxcr4 antagonists
CN101365336B (zh) 增强化疗的方法
US9532984B2 (en) Therapeutic combination for cancer treatment
US20150157645A1 (en) Combination of a 17-alpha-hydroxylase (c17,20-lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
US20220323423A1 (en) Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
AU672288B2 (en) Rejection inhibitor for transplants and IL-1 production inhibitor
RU2780320C2 (ru) Применение антагонистов cxcr4
JP2021059583A (ja) Ｃｘｃｒ４拮抗薬の使用
US11406605B2 (en) Therapeutic compositions for treating pancreatic cancer
TWI846676B (zh) 用於治療胰腺癌的治療組合物
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
JP2009062329A (ja) ホモピペラジン誘導体を有効成分とする糖化最終産物形成阻害剤
JP2007320866A (ja) 糖化蛋白形成阻害剤
MX2008002374A (en) Methods to enhancechemotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140219